bioactiv
molecul
start
point
futur
drug
case
identifi
optim
two
clearli
separ
step
first
small
molecul
synthes
chemic
isol
natur
sourc
biochem
properti
investig
bioassay
figur
step
repeat
iter
optim
process
accordingli
classic
process
lead
discoveri
character
strict
separ
gener
chemic
librari
screen
biolog
activ
cellular
assay
last
two
decad
howev
altern
concept
drug
discoveri
emerg
aim
integr
chemic
synthesi
approach
exploit
molecular
recognit
reactiv
fragment
protein
assembl
chemic
ligand
identif
bioactiv
fragment
combin
therefor
denomin
fragment
ligat
fragment
ligat
attract
altern
classic
drug
discoveri
sever
reason
combin
chemic
synthesi
bioassay
one
step
consider
confin
effort
chemic
synthesi
activ
fragment
combin
thu
highli
effici
save
time
money
energi
chemic
resourc
small
librari
hundr
thousand
reactiv
fragment
requir
cover
relev
chemic
space
test
huge
number
potenti
fragment
combin
fragment
ligat
product
moreov
fragment
ligat
enabl
detect
fragment
spatial
resolv
protein
bind
site
sinc
bind
reactiv
primari
fragment
protein
probe
amplifi
bind
secondari
fragment
precis
defin
locat
review
present
current
state
futur
potenti
fragment
ligat
drug
discoveri
purpos
propos
comprehens
definit
fragment
ligat
chemic
reaction
two
small
molecul
fragment
util
protein
surfac
catalyst
acceler
format
protein
ligand
increas
bind
affin
defin
fragment
ligat
definit
encompass
revers
irrevers
ligat
reaction
consid
combin
coverag
reaction
type
fit
approach
templat
ligat
share
biophys
principl
pose
challeng
detect
product
contribut
excel
exampl
drug
discoveri
process
moreov
definit
creat
clear
distinct
templat
fragment
ligat
catalyt
transform
exert
protein
similar
enzym
substrat
remark
fragment
ligat
reaction
follow
definit
establish
mode
action
sever
clinic
admit
drug
suggest
reaction
inde
proceed
effici
physiolog
condit
exampl
drug
carbidopa
bind
enzym
dopa
decarboxylas
react
cofactor
pyridox
phosphat
form
hydrazon
activ
inhibitor
figur
likewis
anticonvuls
drug
vigabatrin
react
mode
cofactor
gaba
transaminas
form
michael
acceptor
intermedi
lead
irrevers
inhibit
enzym
figur
b
exampl
fragment
ligat
admit
drug
found
react
cofactor
fad
depress
target
monoamin
oxidas
isoniazid
react
nad
mycobacterium
tuberculosi
catalas
fragment
ligat
driven
thermodynam
interact
fragment
protein
section
consid
biophys
basi
fragment
ligat
highlight
conceptu
potenti
method
special
emphasi
given
detect
product
fragment
ligat
reaction
major
gener
challeng
fragment
ligat
assay
section
section
give
overview
chemic
reaction
use
far
templat
ligat
also
discuss
possibl
futur
extens
reaction
set
revers
reaction
studi
context
dynam
coval
irrevers
reaction
also
denomin
synthesi
tg
treat
togeth
reaction
categori
deliv
exampl
templat
fragment
ligat
mani
case
difficult
categor
one
reaction
unambigu
repres
recent
applic
templat
ligat
drug
discoveri
report
section
thu
demonstr
far
method
develop
date
final
section
discuss
current
state
fragment
ligat
consid
strength
method
requir
succeed
complementar
method
classic
ligand
screen
method
consid
therebi
lead
outlook
relev
develop
fragment
ligat
futur
drug
discoveri
fragment
ligat
protein
serv
catalyst
assembl
protein
ligand
fragment
molecul
fragment
chemic
reactiv
link
coval
yield
fragment
combin
improv
bind
affin
biolog
activ
process
requir
chemic
reactiv
dynam
system
abl
adapt
molecular
level
format
case
revers
coval
chemic
bond
evolv
thermodynam
favor
state
thu
furnish
optim
protein
ligand
adapt
system
consid
exampl
molecular
learn
term
learn
appli
describ
adapt
chemic
evolv
system
addit
free
bind
energi
drive
forc
fragment
ligat
figur
two
fragment
bind
protein
independ
without
overlap
free
energi
bind
link
two
fragment
revers
irrevers
chemic
reaction
form
ligat
product
free
bind
energi
x
repres
deviat
addit
bind
energi
provid
coval
link
two
fragment
addit
obtain
fragment
combin
product
display
bind
affin
product
bind
affin
fragment
k
de
k
exampl
two
fragment
k
valu
mm
result
fragment
ligat
product
fact
fragment
combin
also
strongli
superaddit
result
addit
bind
energi
linker
entrop
gain
result
even
stronger
enhanc
bind
likewis
link
two
fragment
reduc
bind
energi
ligat
product
addit
linker
contribut
unfavor
bind
analyt
detect
fragment
constitut
major
challeng
signific
limit
develop
exploit
method
drug
discoveri
main
reason
detect
problem
low
affin
fragment
requir
high
fragment
concentr
gener
possibl
satur
detect
signal
assay
fluoresc
anisotropi
satur
transfer
differ
std
nmr
high
protein
concentr
use
instead
satur
bind
ligand
compar
method
without
ligat
detect
problem
howev
significantli
reduc
fragment
ligat
due
higher
affin
fragment
ligat
product
form
result
fragment
ligat
assay
principl
detect
even
fragment
would
identifi
fragment
assay
exampl
concentr
limit
gener
fragment
present
concentr
exceed
dissoci
constant
k
valu
factor
least
strong
satur
detect
signal
measur
contrast
case
fragment
ligat
assay
concentr
start
fragment
k
valu
typic
use
effect
partial
inhibit
satur
format
stronger
bind
ligat
product
although
detect
fragment
ligat
product
therebi
strongli
facilit
compar
singl
fragment
remain
challeng
sever
reason
ligat
product
possess
higher
bind
affin
start
fragment
target
protein
format
autoinhibitori
amount
ligat
product
limit
strictli
concentr
protein
templat
result
fragment
ligat
product
detect
strong
background
excess
nonreact
fragment
challeng
aris
reactiv
fragment
fragment
ligat
assay
although
reactiv
fragment
use
dipolar
cycloaddit
reaction
truli
bioorthogon
sever
fragment
ligat
reli
electrophil
might
also
react
protein
nucleophil
reaction
partner
control
experi
distinguish
effect
one
fragment
effect
fragment
combin
routin
conduct
avoid
interfer
reaction
assay
addit
gener
recommend
hit
valid
use
independ
secondari
assay
detect
hit
fragment
sever
classic
analyt
method
wide
appli
adapt
detect
templat
fragment
ligat
figur
studi
field
use
liquid
chromatographi
usual
combin
mass
spectrometri
exampl
specif
method
nmr
spectroscopi
addit
fragment
ligat
studi
final
power
complement
detect
fragment
ligat
product
variou
bioassay
develop
recent
detect
fragment
ligat
product
becom
substanti
easier
last
two
decad
rapid
develop
method
term
chromatograph
separ
sensit
mass
detect
also
quantif
structur
elucid
ligat
product
facilit
use
chromatographi
techniqu
limit
remain
howev
chromatograph
separ
take
time
detect
best
suit
irrevers
ligat
case
revers
form
ligat
product
chemic
fixat
chemic
reaction
ph
shift
option
strategi
follow
exampl
semin
report
huc
lehn
virtual
chemic
librari
unstabl
imin
ligat
product
convert
stabl
amin
chemic
reduct
ligat
second
limit
detect
aris
buffer
system
use
fragment
ligat
reaction
mani
buffer
ion
use
ligat
assay
interfer
detect
ligat
product
mass
detector
wherea
buffer
salt
ammonium
formiat
acet
highli
compat
may
interfer
ligat
reaction
ad
reactiv
nucleophil
strong
excess
recent
year
detect
fragment
nativ
protein
ms
develop
matur
technolog
like
method
also
use
detect
fragment
ligat
nmr
spectroscopi
big
advantag
lc
monitor
ligat
reaction
directli
assay
solut
standard
nmr
spectroscopi
requir
high
mm
concentr
fragment
ligat
product
volum
around
ml
chemic
analysi
larg
amount
protein
therefor
method
applic
protein
avail
larg
quantiti
experi
low
throughput
conduct
throughput
enhanc
mixtur
reactiv
fragment
employ
undergo
revers
coval
ligat
mixtur
denomin
dynam
combinatori
librari
dcl
dynam
coval
librari
principl
form
possibl
combin
avail
fragment
build
block
case
n
complementari
reactiv
build
block
number
possibl
product
obtain
protein
templat
shift
equilibrium
favor
best
bind
thu
stabil
ligat
product
detect
one
classic
analyt
method
sever
nmr
method
adapt
specif
detect
fragment
ligat
product
investig
std
nmr
spectroscopi
detect
hemithioacet
form
reaction
aqueou
medium
figur
std
nmr
spectroscopi
method
exploit
select
transfer
proton
magnet
protein
revers
bound
ligand
use
identifi
bind
fragment
dcl
proof
concept
studi
select
target
protein
catalyz
hydrolysi
contain
cystein
residu
activ
site
mixtur
five
thiol
two
aldehyd
employ
therebi
result
potenti
format
ten
hemithioacet
demonstr
bind
strongli
target
enzym
four
thiol
strongli
enhanc
signal
aldehyd
std
format
hemothioacet
surprisingli
bind
two
sugar
could
suppress
addit
substrat
thu
suggest
addit
alloster
bind
site
fragment
signific
inhibit
substrat
hydrolysi
could
confirm
one
combin
also
suggest
format
hemithioacet
activ
inhibitor
anoth
applic
std
nmr
spectroscopi
publish
recent
hirsch
research
recent
nmr
spectroscopi
appli
claridg
detect
fragment
ligat
product
see
figur
section
addit
nmr
spectroscopi
intens
applic
nmr
method
detect
protein
nmr
spectroscopi
use
mani
case
protein
produc
isotop
enhanc
nmr
signal
fragment
bind
observ
exampl
hsqc
experi
perturb
chemic
shift
method
introduc
relationship
sar
nmr
spectroscopi
big
advantag
furnish
inform
bind
site
fragment
signal
nmr
spectra
assign
protein
nmr
spectroscopi
also
valuabl
method
investig
fragment
ligat
reaction
although
could
find
applic
far
crystallographi
found
broad
applic
drug
discoveri
attract
come
detail
structur
inform
reveal
inform
extrem
help
design
fragment
combin
product
sever
studi
far
use
protein
crystallographi
detect
fragment
ligat
rapid
parallel
detect
potent
fragment
ligat
product
form
reaction
final
realiz
introduct
assay
initi
strategi
denomin
dynam
ligat
screen
dl
revers
ligat
reaction
first
investig
dl
increas
sensit
ligand
detect
consider
discoveri
low
affin
fragment
millimolar
k
valu
realiz
figur
detect
method
requir
minim
amount
protein
usual
low
nanomolar
concentr
protein
suffici
conduct
use
standard
assay
equip
microtit
plate
autom
pipet
devic
use
handl
fragment
librari
enzym
assay
sensit
enhanc
catalyt
activ
protein
target
result
rapid
turnov
mani
fluorogen
chromogen
substrat
molecul
fluoresc
reson
energi
transfer
fret
also
use
detect
fragment
reach
highest
sensit
primari
reactiv
fragment
ad
enzym
assay
concentr
result
inhibit
therebi
leav
measur
window
detect
enhanc
inhibit
addit
secondari
fragment
variou
bioassay
format
far
adapt
dynam
ligat
screen
figur
alreadi
describ
fluorogen
substrat
use
competit
assay
compet
fragment
ligat
product
enzym
bind
site
assay
best
fragment
combin
result
strongest
inhibit
enzymat
reaction
figur
altern
substrat
construct
reactiv
group
allow
fragment
ligat
ligat
fragment
increas
affin
substrat
target
protein
assay
figur
b
enabl
detect
fragment
secondari
bind
site
lead
acceler
turnov
competit
binder
also
detect
assay
format
special
case
reactiv
fluorogen
molecul
complet
inact
without
ligat
fragment
denomin
presubstr
especi
sensit
detect
chemic
unstabl
transient
ligat
product
hemiacet
method
use
success
identif
bind
fragment
serin
protein
tyrosin
phosphatas
ptp
capabl
detect
specif
binder
start
point
construct
inhibitor
principl
detect
fragment
ligat
product
also
extend
enzymat
assay
protein
bind
assay
thu
enabl
identif
ligand
site
assay
princip
conduct
either
homogen
solut
heterogen
attach
one
bind
partner
solid
phase
surfac
homogen
assay
ligat
reaction
demonstr
use
fluoresc
polar
fp
also
known
fluoresc
anisotropi
detect
figur
c
assay
reactiv
peptid
fragment
label
fluorophor
fp
ligand
nm
dissolv
buffer
contain
target
protein
concentr
lead
ligand
bind
librari
fragment
screen
modul
fp
assay
enabl
identif
compet
figur
c
enhanc
fragment
figur
singl
experi
templat
effect
exert
protein
quantifi
best
enhanc
fragment
combin
reduct
amin
label
fragment
best
enhanc
fragment
result
picomolar
inhibitor
similar
enzym
inhibit
assay
homogen
assay
fp
assay
conduct
equip
small
assay
volum
low
nm
protein
concentr
provid
ligand
suffici
affin
avail
start
point
homogen
assay
attract
complement
detect
bioactiv
fragment
ligat
product
exampl
thermal
shift
assay
use
increasingli
detect
method
monitor
defold
melt
protein
increas
temperatur
use
fluorophor
show
increas
fluoresc
come
contact
hydrophob
core
unfold
protein
fragment
bind
observ
signific
enhanc
protein
melt
temperatur
free
bind
energi
ligand
even
thermodynam
inform
bind
fragment
reveal
isotherm
titrat
calorimetri
futur
studi
like
use
requir
larg
quantiti
protein
conduct
low
heterogen
assay
appli
investig
bind
method
respect
fragment
howev
coval
immobil
label
affin
probe
biotin
recent
detect
fragment
ligat
product
extend
protein
assay
even
complex
cellular
ohkanda
report
intracellular
gener
inhibitor
protein
intracellular
oxim
ligat
figur
protein
involv
interact
ppi
especi
difficult
inhibit
interact
larg
dynam
interact
surfac
disrupt
molecul
still
abl
penetr
cell
cellular
uptak
author
realiz
reactiv
aldehyd
deriv
fusicoccin
fc
bind
hydrophob
caviti
adjac
bind
site
peptid
contain
hydroxylamin
function
abl
demonstr
templat
format
heterobival
ligat
product
potent
oxim
inhibitor
vitro
presenc
protein
next
author
investig
intracellular
format
stabli
transform
flag
cell
line
hplc
analysi
show
format
cell
treat
led
highest
cytotox
effect
contrast
chemic
synthes
inact
cell
possibl
larg
molecular
size
imped
properti
figur
thu
studi
demonstr
even
larg
molecul
potenti
modul
ppi
gener
intracellular
fragment
ligat
summari
consider
progress
made
detect
method
last
year
especi
method
also
classic
analyt
method
biophys
detect
strategi
facilit
identif
bioactiv
fragment
ligat
product
enzymat
cellular
assay
develop
enabl
discoveri
exampl
templat
fragment
ligat
reaction
futur
therebi
contribut
success
applic
fragment
ligat
assay
numer
reaction
type
far
employ
templat
fragment
ligat
give
overview
reaction
type
focus
recent
addit
repertoir
give
outlook
extens
reason
expect
practic
viewpoint
degre
revers
ligat
reaction
import
criterium
affect
detect
isol
ligat
product
thu
reaction
type
use
templat
fragment
ligat
categor
accord
revers
tabl
addit
heteronucleophil
aliphat
aromat
aldehydesketon
typic
repres
revers
ligat
reaction
equilibr
rapidli
aqueou
solut
result
low
activ
barrier
howev
mark
differ
respect
revers
kinet
depend
react
nucleophil
hemiacet
hemithioacet
rapidli
form
water
aldehyd
alcohol
thiol
templat
fragment
ligat
although
isol
stabl
ligat
format
hemiacet
hemithioacet
ligat
product
imped
competit
heteronucleophil
high
molar
excess
water
furnish
hydrat
altern
reaction
product
nevertheless
could
demonstr
use
nmr
protein
templat
abl
shift
ligat
equilibrium
thu
enabl
identif
hemiacet
hemithioacet
ligat
contrast
hemiacet
full
acet
dithioacet
obtain
addit
two
alcohol
thiol
nucleophil
one
carbonyl
group
report
templat
ligat
product
expect
form
high
activ
barrier
carboc
intermedi
mani
templat
ligat
reaction
involv
nitrogen
nucleophil
react
carbonyl
electrophil
addit
primari
amin
aldehyd
furnish
hemiamin
intermedi
react
form
imin
format
also
process
equilibr
rapidli
requir
nonproton
amin
thu
process
depend
pka
valu
amin
nucleophil
ph
valu
reaction
buffer
imin
consider
stabl
hemiacet
especi
form
aromat
amin
even
isol
case
one
consequ
increas
stabil
imin
equilibr
dynam
combinatori
librari
may
take
significantli
longer
equilibr
hemiacet
hemithioacet
stabil
ligat
product
enhanc
aldehyd
carri
acid
atom
allow
format
enamin
anoth
possibl
chemic
fixat
imin
irrevers
reaction
exampl
reduct
amin
yield
secondari
stabil
ligat
product
nitrogen
nucleophil
aldehyd
elev
case
hydroxylamin
hydrazin
acyl
form
product
oxim
acyl
hydrazon
stabl
physiolog
ph
valu
isol
standard
procedur
column
chromatographi
accordingli
ligat
reaction
equilibr
slowli
anilin
ad
catalyst
format
hydrazin
altern
equilibr
acyl
hydrazon
acceler
addit
ligat
heteronucleophil
aldehyd
await
investig
exampl
thiol
ad
imin
furnish
n
ligat
equilibrium
possibl
shift
interact
protein
bioactiv
data
obtain
investig
presubstr
suggest
trimer
complex
aldehyd
amin
thiol
stronger
affin
protein
target
express
reduc
k
valu
increas
turnov
enzym
likewis
observ
superaddit
bind
inhibit
peptid
aldehyd
amin
quantifi
fp
assay
interpret
format
thioamin
mannich
base
special
form
stabl
amin
also
expect
suitabl
reaction
topic
current
investig
group
templat
fragment
ligat
involv
addit
heteronucleophil
c
electrophil
aldehyd
addit
report
sever
case
product
usual
isol
even
though
reaction
revers
product
favor
retroaddit
alkyl
usual
truli
irrevers
ligat
case
thiolat
employ
nucleophil
highest
reactiv
aliphat
halogenid
epoxid
sulfon
use
studi
suggest
altern
c
electrophil
use
reaction
exampl
nucleophil
substitut
aryl
moieti
could
interest
extens
reaction
repertoir
boric
acid
boron
acid
use
altern
electrophil
use
diol
bisnucleophil
furnish
boron
ester
ligat
product
limit
popular
exampl
revers
reaction
furnish
stabl
product
isol
disulfid
format
disulfid
exchang
reaction
use
thiolat
reactiv
nucleophil
slightli
basic
nonreduc
similar
exchang
reaction
thiolat
report
thioester
exchang
reaction
special
interest
templat
ligat
extend
choic
divers
access
ligat
product
consider
exampl
report
date
describ
revers
templat
addit
nitroalkan
aldehyd
form
secondari
alcohol
prefer
acyl
lipas
protein
target
although
report
templat
aldol
reaction
yet
publish
reaction
type
highli
suitabl
fragment
ligat
chemistri
consid
detail
literatur
aldol
reaction
water
mild
reaction
likewis
addit
cyanid
anion
isocyanid
report
water
suggest
passerini
ugi
reaction
might
highli
suitabl
reaction
appli
bond
format
alken
alkyn
metathesi
reaction
far
demonstr
ligat
reaction
classic
exampl
irrevers
templat
reaction
report
dipolar
cycloaddit
reaction
includ
ligat
furnish
ligat
provid
sulfonylamid
cyclic
clear
numer
ligat
base
cycloaddit
reaction
may
also
succeed
besid
cycloaddit
reaction
howev
irrevers
ligat
yet
investig
much
futur
extens
necessari
provid
ligat
product
cover
larger
part
biolog
relev
chemic
space
gener
chemoselect
reaction
water
requir
success
ligat
ideal
reaction
provid
linker
react
fragment
support
bind
least
interfer
exampl
structur
analysi
world
drug
index
collect
molecul
report
bioactiv
reveal
amid
linkag
privileg
linker
bioactiv
thu
amid
reaction
consid
especi
use
extens
fragment
ligat
repertoir
recent
first
amid
reaction
reaction
type
could
consider
extend
opportun
fragment
ligat
reaction
abl
connect
fragment
without
linker
remain
product
reaction
reaction
form
heterocycl
connect
two
fragment
instead
classic
linker
moieti
defin
fragment
ligat
reaction
explain
biophys
background
use
detect
strategi
underli
chemic
transform
go
focu
applic
concept
discoveri
optim
protein
ligand
start
revers
ligat
reaction
proceed
irrevers
one
mani
first
applic
revers
templat
fragment
ligat
report
dynam
combinatori
librari
dcl
recent
repres
exampl
line
research
highlight
studi
hirsch
author
employ
endothiapepsin
target
model
enzym
aspart
acid
proteas
nine
hydrazid
one
bisaldehyd
use
form
dynam
librari
deriv
two
fragment
bind
adjac
bind
pocket
endothiapepsin
figur
eas
analysi
two
sublibrari
form
consist
four
five
hydrazid
hplc
employ
analyz
templat
format
bisacylhydrazon
ligat
product
presenc
endothiapepsin
potenti
differ
bisacylhydrazon
monoacylhydrazon
possibl
fragment
combin
show
signific
amplif
hplc
signal
presenc
endothiapepsin
templat
two
found
combin
synthes
test
biochem
assay
report
activ
best
inhibitor
show
increas
potenc
compar
start
fragment
thu
illustr
success
exampl
templat
ligat
reaction
author
demonstr
studi
unlik
fragment
optim
method
fragment
grow
merg
templat
fragment
ligat
especi
sensit
discov
combin
fragment
superaddit
ligand
effici
maintain
improv
approach
challeng
lay
preserv
bind
mode
fragment
find
linker
provid
addit
interact
target
despit
posit
result
studi
also
demonstr
limit
dcl
name
tediou
analysi
complex
combinatori
mixtur
limit
dynam
reaction
deliv
product
acylhydrazon
limit
display
studi
claridg
appli
nmr
spectroscopi
detect
serin
proteas
inhibitor
studi
recruit
model
enzym
boron
acid
ligat
ad
sugar
molecul
form
improv
enzym
inhibitor
format
ternari
complex
enzym
boron
acid
sugar
diol
monitor
nmr
observ
gradient
spectroscopi
find
encourag
group
schofield
claridg
appli
nativ
mass
spectrometri
detect
hit
dcl
revers
form
boron
ester
identifi
inhibitor
prolyl
hydroxylas
domain
isoform
enzym
oxygenas
famili
figur
oxygenas
help
regul
human
hypox
respons
thu
make
excel
drug
target
treatment
anemia
diseas
experi
heterocycl
boron
acid
fragment
incub
sever
pool
diol
ligand
subsequ
analyz
nativ
ms
fragment
combin
identifi
shift
protein
mass
convert
stabl
inhibitor
use
suzuki
reaction
result
inhibitor
enzym
activ
nanomolar
rang
result
fragment
ligat
assay
valid
anoth
studi
use
nmr
base
tether
approach
classic
exampl
revers
templat
fragment
ligat
use
disulfid
exchang
method
exploit
revers
disulfid
exchang
reaction
natur
engin
cystein
residu
protein
surfac
fragment
solut
develop
erlanson
group
use
extend
made
approach
even
applic
fragment
combin
report
inhibitor
screen
target
aurora
kinas
figur
first
step
introduc
cystein
residu
near
atp
bind
site
next
extend
synthes
contain
two
residu
diaminopyridin
group
known
bind
purin
bind
site
one
disulfid
residu
abl
react
exchang
introduc
cystein
residu
one
abl
bind
secondari
disulfid
fragment
secondari
fragment
abl
interact
adapt
region
protein
adjac
extend
thermodynam
stabil
disulfid
bond
form
stabil
complex
subsequ
detect
ms
measur
modif
protein
mass
experi
librari
contain
roughli
fragment
screen
pool
compound
result
identif
sever
fragment
combin
modif
correspond
fragment
led
format
stabl
inhibitor
affin
micromolar
rang
similar
approach
success
appli
anoth
kinas
protein
attach
extend
irrevers
alkyl
dynam
ligat
screen
introduc
overcom
detect
limit
combinatori
method
dcl
first
detect
dynam
form
fragment
ligat
product
demonstr
sar
coronaviru
main
proteas
mpro
figur
mpro
cystein
proteas
essenti
replic
viru
insid
infect
host
cell
inhibitor
target
mpro
therefor
relev
potenti
sinc
proteas
possess
defin
bind
pocket
side
chain
peptid
possibl
develop
peptid
aldehyd
inhibitor
posit
electrophil
aldehyd
precis
activ
site
proteas
dynam
ligat
screen
fragment
librari
divers
nucleophil
reveal
sever
fragment
hit
target
pocket
enzym
k
valu
millimolar
rang
best
fragment
hit
convert
correspond
aldehyd
fragment
assay
enhanc
inhibit
amin
librari
therebi
provid
secondari
hit
fragment
adjac
pocket
enzym
bind
site
two
iter
dynam
ligat
screen
start
peptid
inhibitor
result
select
two
fragment
coval
combin
fragment
reduct
amin
reveal
entir
nonpeptid
inhibitor
mpro
k
valu
exampl
dynam
ligat
assay
summar
tabl
caspas
protein
play
essenti
role
execut
phase
cell
apoptosi
therefor
potenti
drug
target
traumat
brain
injuri
amyotroph
later
sclerosi
well
alzheim
parkinson
diseas
protein
test
nanomolar
peptidyl
ketoaldehyd
inhibitor
total
fragment
includ
nucleophil
primari
amin
microtit
plate
appli
fp
bind
assay
describ
observ
chang
fragment
test
fragment
led
lower
fp
signal
neg
cooper
fragment
evok
significantli
stronger
fp
signal
posit
cooper
control
fragment
confirm
competit
inhibitor
k
best
cooper
bind
fragment
b
link
coval
start
ligand
reduct
amin
therebi
result
potent
inhibitor
k
valu
pm
dynam
ligat
assay
implement
screen
four
close
relat
protein
tyrosin
phosphatas
ptp
human
mycobacteri
gener
develop
specif
ptp
inhibitor
consid
major
challeng
rais
doubt
druggabl
physiolog
relev
class
enzym
use
phosphat
electrophil
ptp
substrat
specif
bind
fragment
could
identifi
ptp
librari
primari
amin
specif
secondari
site
binder
detect
use
dynam
substrat
enhanc
assay
see
figur
b
activ
fragment
form
ligat
product
ptp
substrat
result
higher
stabil
complex
lower
k
valu
lead
amplifi
releas
phosphat
ion
determin
malachit
green
assay
replac
phenyl
phosphat
substrat
noncleav
phosphotyrosin
mimet
coval
link
select
amin
fragment
furnish
inhibitor
protein
tyrosin
phosphatas
mptpa
mycobacterium
tuberculosi
activ
three
ptp
result
suggest
target
ptp
enabl
develop
select
ptp
inhibitor
dynam
ligat
screen
extend
toward
aspart
proteas
time
employ
fluoresc
reson
energi
transfer
fret
peptid
aldehyd
use
direct
probe
identifi
bind
fragment
aspart
proteas
enzym
known
main
culprit
aggreg
major
patholog
hallmark
alzheim
diseas
ad
thu
consider
effort
made
discov
inhibitor
potenti
therapeut
treatment
ad
instead
revers
hemithioacet
format
aldehyd
hydrat
form
bind
catalyt
aspart
acid
dyad
format
hydrogen
bond
dynam
ligat
peptid
aldehyd
amin
nucleophil
revers
yield
imin
product
peptid
aldehyd
serv
chemic
reactiv
inhibitor
cri
reveal
competit
inhibitor
identifi
aminophenyl
coumarin
fragment
use
start
point
hit
optim
low
micromolar
k
inhibitor
develop
anoth
applic
detect
report
recent
aspart
proteas
recent
applic
revers
fragment
ligat
extend
toward
discoveri
irrevers
inhibitor
enterovir
proteas
figur
epoxyaldehyd
modifi
partial
structur
known
inhibitor
cystein
proteas
weak
irrevers
inhibitor
proteas
coxsacki
viru
test
librari
primari
amin
fragment
discov
fragment
hit
led
superaddit
inhibit
proteas
coval
modif
enzym
addit
fragment
iter
optim
ligat
product
final
led
inhibitor
enterovir
proteas
acceler
protein
deactiv
rate
signific
nonvir
proteas
earli
studi
area
irrevers
fragment
ligat
conduct
sharpless
group
denomin
kinet
synthesi
use
dipolar
cycloaddit
azid
alkyn
situ
click
reaction
templat
protein
acetylcholinesteras
ach
target
treatment
alzheim
studi
method
appli
target
goal
identifi
synthes
fragment
combin
occupi
activ
center
peripher
bind
site
figur
start
point
establish
ach
inhibitor
tacrin
use
bind
activ
center
enzym
tacrin
modifi
introduc
azid
function
compound
collect
termin
acetylen
compos
peripher
site
bind
fragment
test
detect
format
dipolar
cycloaddit
first
result
confirm
protein
templat
effect
ligat
reaction
bound
fragment
presenc
enzym
syn
triazol
form
littl
background
reaction
confirm
reaction
singl
fragment
pair
author
turn
attent
reaction
contain
mixtur
acetylen
compound
inde
protein
templat
induc
format
highli
potent
fragment
combin
dissoci
constant
low
picomolar
even
femtomolar
rang
ligat
also
appli
protein
exampl
format
known
nanomolar
inhibitor
hiv
proteas
contain
acceler
presenc
case
reaction
consider
slower
report
ach
inhibitor
time
clear
background
reaction
furnish
observ
click
reaction
also
success
appli
abl
tyrosin
fukas
research
group
demonstr
templat
synthesi
function
mimet
domain
inhibit
growth
cancer
cell
obtain
best
inhibitor
templat
reaction
azid
alkyn
fragment
crucial
exclud
even
tini
amount
copper
ion
reaction
group
miyata
finn
report
situ
synthesi
inhibitor
histon
deacetylas
alkyn
fragment
bear
hydroxam
azid
surprisingli
form
ligat
product
best
inhibitor
far
contain
instead
activ
detail
scrutini
result
reveal
reaction
contain
trace
cui
ion
bound
site
suffici
catalyz
reaction
cycloaddit
product
addit
ligat
dipolar
cycloaddit
also
investig
reaction
thioacid
sulfonylazid
fragment
provid
acylsulfonamid
via
cyclic
intermedi
constitut
especi
success
exampl
denomin
reaction
manetsch
group
demonstr
irrevers
ligat
reaction
particularli
challeng
target
ppi
domain
interact
peptid
crucial
step
regul
apoptosi
program
cell
death
inhibitor
interact
might
potent
anticanc
agent
screen
new
modul
protein
use
templat
reaction
sulfonylazid
thioacid
fragment
figur
could
shown
format
micromolar
inhibitor
proceed
reaction
less
inhibitor
form
without
protein
block
bind
site
peptid
addit
inact
mutat
peptid
effect
irrevers
fragment
ligat
recent
establish
format
amid
bond
amid
reaction
one
relev
fragment
linkag
bioactiv
compound
clinic
admit
drug
figur
collect
activ
ester
cover
broad
rang
chemic
reactiv
incub
protein
factor
xa
drug
target
blood
coagul
cascad
discov
condit
amid
reaction
two
activ
ester
fragment
phenyl
ester
trifluoroethyl
ester
display
clear
amid
substrat
competit
assay
afford
nanomolar
inhibitor
two
weakli
bind
fragment
millimolar
affin
chromatographi
qtof
detector
use
quantifi
progress
format
inhibitor
interestingli
reaction
trifluoroethyl
ester
proceed
without
detect
background
reaction
autoinhibit
satur
concentr
nm
free
inhibitor
inhibitor
display
remark
superaddit
enhanc
free
bind
energi
k
valu
nm
instead
addit
case
proven
result
rel
decreas
entropi
bind
fragment
link
complex
crystal
obtain
structur
allow
author
ration
templat
amid
reaction
steric
mechanist
detail
fragment
ligat
establish
altern
complementari
rout
access
bioactiv
protein
ligand
recent
year
signific
progress
realiz
sever
front
improv
special
analyt
bioanalyt
method
contribut
broad
implement
profound
understand
method
chemic
scope
ligat
reaction
continu
extend
extens
reaction
deliv
templat
fragment
ligat
product
expect
review
biophys
background
underli
chemistri
actual
applic
method
consid
strength
limit
final
give
outlook
futur
possibl
develop
techniqu
part
drug
discoveri
process
biggest
advantag
fragment
ligat
compar
method
enabl
spatial
resolv
identif
fragment
bind
precis
defin
protein
pocket
method
exampl
crystallographi
method
also
deliv
structur
inform
ligand
bind
howev
use
screen
specif
one
bind
site
fragment
detect
realiz
structur
defin
bind
reactiv
start
fragment
second
major
advantag
fragment
ligat
assay
sensit
caus
addit
bind
enhanc
ligat
fragment
result
fragment
ligat
assay
identifi
fragment
detect
discoveri
method
consider
higher
fragment
protein
concentr
thu
method
may
provid
protein
ligand
altern
structur
improv
ligand
effici
third
advantag
fragment
ligat
practic
econom
benefit
mainli
aris
integr
synthesi
fragment
combin
detect
bioactiv
one
step
result
effort
resourc
requir
chemic
synthesi
bioactiv
ligand
reduc
consider
bioactiv
fragment
combin
need
resynthes
structur
function
valid
wherea
classic
screen
use
larg
librari
molecul
cover
chemic
space
fragment
ligat
screen
need
small
librari
reactiv
fragment
sampl
chemic
space
potenti
fragment
combin
one
gener
requir
fragment
ligat
assay
need
reactiv
start
fragment
could
problemat
suitabl
ligand
target
protein
known
case
complementari
method
classic
screen
design
indispens
provid
start
point
fragment
ligat
anoth
major
requir
ligat
assay
avail
ligat
reaction
cover
relev
chemic
space
compat
condit
protein
assay
although
shown
section
number
chemic
reaction
adapt
fragment
ligat
screen
constantli
grow
continu
research
effort
need
make
privileg
fragment
linkag
access
ligat
assay
particular
reaction
format
heterocycl
direct
connect
cyclic
fragment
often
construct
reaction
need
investig
critic
evalu
show
fragment
ligat
current
consid
broadli
applic
method
contribut
modern
drug
discoveri
process
complement
establish
success
method
specif
virtu
requir
spatial
resolv
screen
high
sensit
identif
novel
fragment
well
chemic
develop
known
protein
ligand
futur
research
show
specif
advantag
method
abl
provid
clinic
candid
improv
properti
ultim
signific
fragment
ligat
depend
extent
contribut
fulfil
promis
drug
discoveri
find
better
drug
high
potenc
specif
fewer
relat
side
effect
like
fragment
ligat
contribut
goal
close
collabor
classic
lead
discoveri
approach
beyond
practic
success
method
drug
discoveri
process
ligat
reaction
also
potent
attract
research
train
tool
teach
us
partial
structur
molecul
interact
addit
creat
protein
ligand
method
help
us
understand
molecular
recognit
make
molecul
life
work
molecular
evolut
proceed
author
declar
conflict
interest
rademann
studi
chemistri
biochemistri
univers
constanc
germani
rutger
univers
nj
usa
complet
phd
richard
r
schmidt
univers
constanc
synthesi
oligosaccharid
postdoctor
research
carlsberg
laboratori
copenhagen
denmark
morten
meldal
klau
bock
establish
group
studi
use
polym
reagent
organ
medicin
chemistri
becam
professor
medicin
chemistri
freie
berlin
team
set
one
first
academ
screen
facil
europ
leibniz
institut
molecular
pharmacolog
fmp
chair
medicin
chemistri
univers
leipzig
becam
full
professor
freie
berlin
mike
jaegl
ee
lin
wong
carolin
tauber
eric
nawrotzki
phd
student
group
come
academ
background
chemistri
pharmaci
molecular
biolog
univers
freiburg
mj
johor
bahru
taipei
seoul
elw
berlin
ct
leipzig
en
work
project
involv
reaction
variou
protein
target
includ
proteas
phosphatas
interact
christoph
arkona
studi
biochemistri
leibniz
univers
hannov
join
group
senior
scientist
finish
phd
plant
biochemistri
mani
year
drug
develop
biotech
industri
photo
show
left
right
mike
jaegl
eric
nawrotzki
rademann
carolin
tauber
christoph
arkona
ee
lin
wong
